BNTX delivered its Q2 results on August 4 and the market's verdict was swift — the stock slipped roughly 1% on the day and has now shed 6% over the past month, with analysts moving quickly to pare back their price targets even as they held their constructive ratings.
The analyst response to the print tells the clearest story this week. Two firms moved within hours of the release: Citigroup trimmed its target from $130 to $125 while holding Buy, and Evercore ISI cut from $135 to $130 while keeping Outperform. Morgan Stanley had already moved earlier in the cycle, dropping its target from $126 to $119 in early July. The direction of travel is consistent — bulls are still bulls, but they are nudging numbers lower. The consensus mean target now sits at $104.44, implying roughly 14% upside from the $91.35 close. That gap is meaningful but not stretched, and Bernstein's market-perform initiation in May at $96 is a reminder that not everyone on the Street sees a compelling risk-reward from these levels. EPS surprise ranks near the top of the universe at the 83rd percentile, while analyst recommendation divergence scores at the 92nd percentile — suggesting the spread of views is unusually wide for a stock of this size.
The options market has retraced from the bullish extreme flagged in last week's note. Ahead of earnings, the put/call ratio had dropped to 0.80, well below its 20-day average of 0.86 — the most call-heavy positioning in nearly a year. Post-print, the PCR has barely moved, holding at 0.80 on August 4, roughly 0.8 standard deviations below that same average. The pre-earnings repositioning toward calls did not flip sharply defensive after the result, which at minimum suggests the reaction did not alarm options traders. The PCR remains well above its 52-week low of 0.45, so there is no crowding into calls here, but the post-earnings read is notably calm.
The lending market remains a non-story. Borrow availability has actually loosened further since the pre-earnings note — now at nearly 4,000% of short interest, up sharply from around 2,400% a week ago. That means roughly 40 shares are available to borrow for every one currently short. Short interest itself eased another 2.3% on the week to around 2.28 million shares. Cost to borrow has fallen to 0.46%, down 23% on the week and its lowest level in several months. None of this points to any meaningful bearish conviction in the lending market. Peers were mixed on the week: SMMT gained nearly 10% and CRSP rose 11.6%, while GLUE dropped 27% on what appears to be a stock-specific move. BNTX's modest 1.2% weekly decline looks unremarkable against that backdrop.
The institutional picture carries one note of interest. T. Rowe Price and FMR (Fidelity) both added meaningfully in the quarter to June 30 — T. Rowe adding 1.37 million shares and FMR adding 1.24 million — while co-founder Ugur Sahin trimmed 1.17 million shares in the same period. The founder reduction is not unusual given the size of his position (still above 15% of shares), but the divergence between institutional buying and founder selling is worth tracking across future filings.
With the next earnings event now dated for early November, the near-term focus shifts to pipeline catalysts — particularly any readouts on BNT323, pumitamig, and BNT326 — and whether the pattern of successive target cuts from positive-rated analysts eventually narrows that consensus gap or simply compresses alongside the stock.
See the live data behind this article on ORTEX.
Open BNTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
